Mirodenafil dihydrochloride (Aribio)

米罗那非二盐酸盐 (Aribio)

Report date: 2024/05/15 14:19:12

Base Information

Drug NameMirodenafil dihydrochloride (Aribio)
Drug Alias NameAR-1001AR1001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 5A inhibitors
TargetsPhosphodiesterase 5A
Therapy Area/IndicationsDepressionAlzheimer DiseaseLewy Body Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[13
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAribio Co Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsDepressionAlzheimer DiseaseLewy Body Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank